Evidence map›Paper›PMID 28931752›Full record

ArticleJCI insight2017

L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor.

Daiki Masukawa, Motokazu Koga, Anna Sezaki, Yuka Nakao, Yuji Kamikubo, Tatsuo Hashimoto, Yuki Okuyama-Oki, Aderemi Caleb Aladeokin, Fumio Nakamura, Utako Yokoyama and 7 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Daiki MasukawaDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Motokazu KogaDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Anna SezakiDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuka NakaoDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuji KamikuboDepartment of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan.
Tatsuo HashimotoDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuki Okuyama-OkiMedical Science and Cardiorenal Medicine, and.
Aderemi Caleb AladeokinDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Fumio NakamuraDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Utako YokoyamaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiromichi WakuiMedical Science and Cardiorenal Medicine, and.
Hiroshi IchinoseGraduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan.
Takashi SakuraiDepartment of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan.
Satoshi UmemuraMedical Science and Cardiorenal Medicine, and.
Koichi TamuraMedical Science and Cardiorenal Medicine, and.
Yoshihiro IshikawaCardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yoshio GoshimaDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yokohama City University · JPCardiovascular Institute Hospital · JPJuntendo University · JPTokyo Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood pressure is regulated by extrinsic factors including noradrenaline, the sympathetic neurotransmitter that controls cardiovascular functions through adrenergic receptors. However, the fine-tuning system of noradrenaline signaling is relatively unknown. We here show that l-3,4-dihydroxyphenylalanine (L-DOPA), a precursor of catecholamines, sensitizes the vascular adrenergic receptor alpha1 (ADRA1) through activation of L-DOPA receptor GPR143. In WT mice, intravenous infusion of the ADRA1 agonist phenylephrine induced a transient elevation of blood pressure. This response was attenuated in Gpr143 gene-deficient (Gpr143-/y) mice. Specific knockout of Gpr143 in vascular smooth muscle cells (VSMCs) also showed a similar phenotype, indicating that L-DOPA directly modulates ADRA1 signaling in the VSMCs. L-DOPA at nanomolar concentrations alone produced no effect on the VSMCs, but it enhanced phenylephrine-induced vasoconstriction and intracellular Ca2+ responses. Phenylephrine also augmented the phosphorylation of extracellular signal-regulated kinases in cultured VSMCs from WT but not Gpr143-/y mice. In WT mice, blood pressure increased during the transition from light-rest to dark-active phases. This elevation was not observed in Gpr143-/y mice. Taken together, our findings provide evidence for L-DOPA/GPR143 signaling that exerts precursor control of sympathetic neurotransmission through sensitizing vascular ADRA1.

Indexed as

AnimalsCalciumCells, CulturedExtracellular Signal-Regulated MAP KinasesEye ProteinsLevodopaMembrane GlycoproteinsMiceMice, KnockoutMuscle, Smooth, VascularMuscle TonusPhenylephrinePhosphorylationReceptors, Adrenergic, alpha-1Receptors, G-Protein-CoupledSignal TransductionCalciumExtracellular Signal-Regulated MAP KinasesEye ProteinsGpr143 protein, mouseLevodopaMembrane GlycoproteinsPhenylephrineReceptors, Adrenergic, alpha-1Receptors, G-Protein-CoupledVasoconstrictor AgentsCell BiologyPharmacologyVascular Biology

Identifiers

PMID28931752
PMCPMC5621878
OpenAlexW2755782089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.